Conferences
ESMO 2023: PSMAfore Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with Metastatic Castration Resistant Prostate Cancer
October 23, 2023
ESMO 2023: Advances in the Molecular Understanding of GU Cancers: The Next Generation of Therapeutic Targets
October 23, 2023
ESMO 2023: Prediction of Toxicity in Current Systemic Treatment of Genitourinary Cancers
October 23, 2023
ESMO 2023: Discussant: TAR-210 & SunRISe-1
October 23, 2023
ESMO 2023: Discussant – ABACUS-2, NEMIO, EV-103 (Cohort-L)
October 23, 2023
ESMO 2023: Discussant - MEDI5752 (Volrustomig) for 1st Line Advanced Clear Cell Renal Cell Carcinoma & TIDE-A
October 23, 2023
ESMO 2023: TIDE-A: Phase II Study of Avelumab plus Intermittent Axitinib in Previously Untreated Patients with mRCC
October 23, 2023
ESMO 2023: SunRISe-1: TAR-200 Monotherapy in Patients With BCG Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer (HR NMIBC)
October 23, 2023
ESMO 2023: Treatment Patterns Among Novel Hormonal Therapy-experienced Patients with mCRPC
October 23, 2023
ESMO 2023: Exposure-Safety Analyses of Talazoparib in Combination of Enzalutamide in Patients with mCRPC in TALAPRO-2 Trial
October 23, 2023
ESMO 2023: 177Lu-PSMA-617 in Pre- and Post-Taxane mCRPC Setting: Results from the Phase II IRST-185.03 Clinical Trial
October 23, 2023